Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885114 | 0.72 | EP300 (0.50) | SMN1; SMN2POLBEP300KAT2BHTT | |
| SCHEMBL30052176 | 0.72 | EP300 (0.50) | SMN1; SMN2POLBEP300KAT2BHTT | |
| SCHEMBL9361699 | 0.69 | ALDH1A1 (0.45) | SMN1; SMN2POLBHTTKDM4ETSHR | |
| SCHEMBL5982117 | 0.68 | BCHE (0.41) | SMN1; SMN2EP300KAT2BKDM4EALDH1A1 | |
| SCHEMBL16794627 | 0.68 | PTK2 (0.45) | SMN1; SMN2POLBEP300KAT2BHTT | |
| SCHEMBL29962532 | 0.68 | PTK2 (0.45) | SMN1; SMN2POLBEP300KAT2BHTT | |
| SCHEMBL29359720 | 0.68 | SMN1; SMN2 (0.44) | SMN1; SMN2POLBEP300KAT2BHTT | |
| SCHEMBL7977989 | 0.68 | CRBN (0.55) | SMN1; SMN2POLBEP300KAT2BHTT | |
| SCHEMBL16794606 | 0.67 | CHEK1 (0.44) | SMN1; SMN2POLBEP300KAT2BHTT | |
| SCHEMBL8466158 | 0.67 | SMN1; SMN2 (0.51) | SMN1; SMN2POLBEP300KAT2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585751-A4 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | CELMED ONCOLOGY USA INC (CA) | 2008-08-13 | — | — | EP | claimed |
| JP-2006514009-A | — | — | 2006-04-27 | — | — | JP | claimed |
| US-20060063743-A1 | Peptide deformylase activated prodrugs | BALLATORE CARLO | 2006-03-23 | — | — | US | claimed |
| EP-1585751-A2 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | Celmed Oncology (USA), Inc. (CA) | 2005-10-19 | — | — | EP | claimed |
| US-20040236096-A1 | Peptide deformylase activated prodrugs | NEWBIOTICS, INC. | 2004-11-25 | — | — | US | claimed |
| WO-2004043400-A2 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | CELMED ONCOLOGY (USA), INC. (CA) | 2004-05-27 | — | — | WO | claimed |
| US-5955100-A | TREATMENT OF MALIGNANT TUMORS, INFLAMMATORY DISEASES, OR AUTOIMMUNE DISEASES | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1999-09-21 | — | — | US | claimed |
| EP-0879605-A2 | GLYCOSYL PRODRUG CONJUGATE WITH ENHANCED TOLERANCE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-11-25 | — | — | EP | claimed |
| US-5621002-A | HAVING A MODIFIED COMPETITIVE ENZYME ACTIVITY INHBITOR LINKED TO A SPACER-DRUG; ENZYME CLEAVAGE AT A LOWER CONCENTRATION, I.E. LOW MICHAELIS-MENTEN CONSTANT(KM) | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | claimed |
| EP-0647450-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-04-12 | — | — | EP | claimed |
| EP-0642799-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | claimed |
| EP-0595133-A2 | Prodrugs, their preparation and use as medicaments | BEHRINGWERKE Aktiengesellschaft (DE) | 1994-05-04 | — | — | EP | claimed |
| JP-3170426-A | — | — | None | — | — | JP | disclosed |
| JP-3170427-A | — | — | None | — | — | JP | disclosed |
| US-20160039842-A1 | OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS | EPIGENETIX, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039842-A1 | OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS | EPIGENETIX, INC. | 2016-02-11 | — | — | US | disclosed |
| EP-0428103-A2 | Prevention of glycoprotein enveloped virus infectivity by pyridyloxazole-2-ones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0428103-A2 | Prevention of glycoprotein enveloped virus infectivity by pyridyloxazole-2-ones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0428103-A2 | Prevention of glycoprotein enveloped virus infectivity by pyridyloxazole-2-ones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0428106-A1 | Novel pyridyloxazole 2-ones useful as proteinkinase C inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063743-A1 | Peptide deformylase activated prodrugs | DNPEP, DPEP1, PEPD | SMN1; SMN2 4166/4885POLB 2828/4885EP300 4426/4885 |
| US-20040236096-A1 | Peptide deformylase activated prodrugs | DNPEP, DPEP1, PEPD | SMN1; SMN2 4308/4885POLB 2784/4885EP300 4360/4885 |
| US-20160039842-A1 | OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | SMN1; SMN2 2843/4885POLB 609/4885EP300 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.